Inscripta
Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.
Founded
2015Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.
Founded with a mission to revolutionize genome engineering, Inscripta is pioneering scalable digital genome engineering through its advanced CRISPR-based platform. The company's core product, the GenoScaler™ Platform, integrates an instrument, consumables, software, and assays to offer a fully automated workflow for massively parallel, trackable editing of genomes. Inscripta aims to harness the power of biology and data science to bring affordable and sustainable synthetic biology products to market, focusing on industries such as biotechnology and pharmaceuticals.
Notable figures associated with Inscripta include leaders in genome engineering and synthetic biology. The company has attracted significant investment from prominent venture capital firms, enabling rapid advancements and scaling of their technology. Key achievements include the development of the MAD7® Nuclease and the successful deployment of their benchtop platform in various research settings. Inscripta's innovations have had a substantial impact on the field of synthetic biology, making genome editing more accessible and efficient.
Companies similar to Inscripta include Synthego, Mammoth Biosciences, Tome Biosciences and Scribe Therapeutics.
Inscripta was founded in 2015.
Inscripta's headquarters is located in Boulder, CO, US.
Inscripta's most recent funding round was for $4.4M (USD) in January 2023.
As of Jan 18, 2023, Inscripta has disclosed funding of $463.9M (USD). Undisclosed round amounts are excluded.
Inscripta has 178 employees as of Feb 4, 2024.
Scribe Therapeutics
scribetx.com
